KEMPHARM INC (KMPH)

US4884452065 - Common Stock

5.81  -0.02 (-0.34%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
12.84M13.29M
3.50%		28.65M
115.58%		11.56M
-59.65%
EBITDA
YoY % growth
-20.04M
63.68%		-4.93M
75.40%		7.986M
261.99%		-39.372M
-593.01%
EBIT
YoY % growth
-20.34M
63.35%		-5.2M
74.43%		7.729M
248.63%		-40.443M
-623.26%
Operating Margin
-158.41%-39.13%26.98%-349.85%
EPS
YoY % growth
-11.84
80.63%		-3.31
72.04%		-0.46
86.10%		-1.12
-143.91%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q4 / 22 Q1 / 23 Q2 / 23 Q3 / 23 Q4 / 23
EPS
Q2Q % growth		-0.18
-121.00%
Revenue
Q2Q % growth		3.264M
26.41%
EBITDA
Q2Q % growth		-6.018M
EBIT
Q2Q % growth		-6.614M
-132.72%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2022
Q2Q % growth		 -0.19
-280.00%		-0.13-0.06-43.29%
Q2 2022
Q2Q % growth		 -0.19
-190.48%		-0.12-0.07-55.23%
Q1 2022
Q2Q % growth		 -0.05
90.74%		-0.060.0110.87%
Q4 2021
Q2Q % growth		 -0.08
92.52%		-0.080.00-4.58%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2022
Q2Q % growth		 2.874M
46.26%		3.264M-390K-11.95%
Q2 2022
Q2Q % growth		 1.3M
-89.15%		1.836M-536K-29.19%
Q1 2022
Q2Q % growth		 3.965M
-67.29%		3.126M839K26.84%
Q4 2021
Q2Q % growth		 2.582M
8.95%		2.28M302K13.25%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS0% 0% 0% -8.37%
Revenue0% 0% 0% -4.62%